MarketCap
Facebook
X
Telegram
Clovis Oncology Income Statement 2021-2009 | CLVS
Brief overview of financial results at Clovis Oncology
The overview follows changes across a five-year period. Clovis Oncology reported revenue of $78 thousand in 2016 and $36 million by 2021. The total change was +46012.8%, with a CAGR of approximately 241%. The annual growth rate indicates an exceptionally strong top-line trend.
The five-year EBITDA result moved by +88.1%: from −372 million dollars to −44.2 million dollars. The operating result developed less favorably than sales. EBITDA margin moved from −476400% to −122.9%. Higher profitability strengthens the quality of operating growth.
The final result was −$349 million initially and −$64.4 million in the final year. The direction improved, yet positive earnings are still absent.
Market capitalization changed from 2.5 billion dollars to 262 million dollars (−89.5%). The market is not yet fully reflecting the fundamental progress.
What the figures show
The financial profile remains mixed, with strengths and risks moving in different directions. The strongest signals are an improving EBITDA margin, net-income growth and a larger revenue base. The overall view is constrained by declining capitalization and a narrow EBITDA buffer. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Clovis Oncology
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
262 M | 764 M | 447 M | 1.32 B | 2.85 B | 2.49 B | 754 M | 2.21 B | 1.86 B | 492 M | 73.1 M | - | - |
Shares |
128 M | 96.7 M | 53.9 M | 52.1 M | 47 M | 38.5 M | 36 M | 33.9 M | 28.7 M | 24.9 M | 3.85 M | 1.32 M | - |
Historical Prices |
2.04 | 7.9 | 8.29 | 25.4 | 60.5 | 64.8 | 20.9 | 65.2 | 65 | 19.7 | 19 | ||
Net Income |
-64.4 M | -99 M | -400 M | -368 M | -346 M | -349 M | -353 M | -160 M | -84.5 M | -74 M | -55.6 M | -37.8 M | -17.1 M |
Revenue |
36 M | 43.3 M | 143 M | 95.4 M | 55.5 M | 78 K | - | 13.6 M | - | - | - | - | - |
Gross Profit |
- | 123 M | 108 M | 73.3 M | 43.8 M | 8 K | - | - | - | - | - | - | - |
Operating Income |
-52.7 M | -65 M | -377 M | -334 M | -238 M | -373 M | -377 M | -158 M | -83.8 M | -73.8 M | -54.6 M | -38.6 M | - |
Interest Expense |
53 K | 202 K | 6.34 M | 7.92 M | 3.64 M | 633 K | 416 K | 2.09 M | -178 K | -4 K | -957 K | 795 K | - |
EBITDA |
-44.2 M | -56.8 M | -369 M | -329 M | -235 M | -372 M | -376 M | -158 M | -83.5 M | -73.4 M | -54.4 M | -38.5 M | - |
Operating Expenses |
88.7 M | 108 M | 131 M | 429 M | 293 M | 373 M | 377 M | 172 M | 83.8 M | 73.8 M | 54.6 M | - | - |
General and Administrative Expenses |
33.3 M | 40.8 M | 183 M | 176 M | 139 M | 40.7 M | 8.24 M | 5.6 M | 16.6 M | 10.6 M | 6.86 M | 4.3 M | - |
All numbers in USD currency
Quarterly Income Statement Clovis Oncology
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | 145 M | 144 M | 138 M | 129 M | 121 M | 108 M | 104 M | 96.7 M | 88.3 M | 80.5 M | 71.7 M | 54.8 M | 54.7 M | 53 M | 52.9 M | 52.7 M | 52.7 M | 52.2 M | 50.6 M | 50 M | 48.9 M | 45.2 M | 44 M | 38.6 M | 38.5 M | 38.4 M | 38.4 M | 38.3 M | 37.6 M | 34.1 M | 34 M | 33.9 M | 33.9 M | 33.9 M | 33.8 M | 31.8 M | 30 M | 26.7 M | 26 M | 25.9 M | 25.9 M | 25.7 M | 22.4 M | 11.5 M | 1.29 M | 1.29 M | 1.25 M |
Net Income |
- | -56 M | -71.3 M | -60.2 M | -64.4 M | -67.4 M | -66.4 M | -66.3 M | -99 M | -78.7 M | -92.2 M | -99.3 M | -99.5 M | -94.1 M | -120 M | -86.4 M | -99.3 M | -89.9 M | -101 M | -77.7 M | -51.9 M | -60.7 M | -175 M | -58.5 M | -70.7 M | -65.7 M | -129 M | -83.4 M | -120 M | -98.6 M | -71.5 M | -63.1 M | -54.9 M | -39.6 M | -34.8 M | -30.7 M | -29.2 M | -20.3 M | -19.3 M | -15.7 M | -21.1 M | -18.3 M | -15.7 M | -19 M | -14.9 M | -13.8 M | -18.5 M | -8.33 M |
Revenue |
- | 30.7 M | 32.1 M | 34.2 M | 36 M | 37.9 M | 36.8 M | 38.1 M | 43.3 M | 38.8 M | 39.9 M | 42.6 M | 39.3 M | 37.6 M | 33 M | 33.1 M | 30.4 M | 22.8 M | 23.8 M | 18.5 M | 17 M | 16.8 M | 14.6 M | 7.04 M | 78 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | 8.27 M | - | - | - | 9.1 M | - | - | - | - | - | 4.77 M | 4.49 M | 4.01 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | -44.2 M | -59.4 M | -50.4 M | -52.7 M | -57.5 M | -57.6 M | -58 M | -65 M | -72.5 M | -82.6 M | -82 M | -91.7 M | -106 M | -93.5 M | -85.2 M | -97 M | -89.2 M | -79 M | -68.7 M | -63.2 M | -60.5 M | -57.7 M | -56.2 M | -67.1 M | -64 M | -157 M | -85 M | -147 M | -97.3 M | -68.3 M | -64.2 M | -53.9 M | -41.1 M | -35 M | -28.5 M | -28.5 M | -20.4 M | -19.3 M | -15.6 M | -21.1 M | -18.2 M | -15.5 M | -19 M | -14.5 M | -13.3 M | -18.4 M | -8.45 M |
Interest Expense |
- | 192 K | 171 K | 148 K | 53 K | 101 K | 107 K | 183 K | 202 K | 79 K | 239 K | 841 K | 1.26 M | 781 K | 1.9 M | 2.4 M | 2.5 M | 2.54 M | 1.48 M | 1.41 M | 1.4 M | 1.29 M | 594 K | 354 K | 160 K | 252 K | 196 K | 25 K | 164 K | 179 K | 62 K | 11 K | 2.09 M | 1.77 M | 270 K | -106 K | -657 K | 55 K | -33 K | -78 K | -4 K | -48 K | -172 K | -4 K | -405 K | -555 K | -115 K | 118 K |
EBITDA |
- | -38.5 M | -55.6 M | -48.4 M | -52.7 M | -51 M | -53.1 M | -55.8 M | -65 M | -66.4 M | -78.5 M | -79.9 M | -91.7 M | -101 M | -89.8 M | -83.5 M | -97 M | -86.7 M | -77.5 M | -68.1 M | -63.2 M | -58.6 M | -56.5 M | -55.5 M | -67.1 M | -63.2 M | -156 M | -84.7 M | -147 M | -96.7 M | -67.4 M | -63.8 M | -53.9 M | -37.3 M | -31.4 M | -25 M | -28.5 M | -20.2 M | -19.2 M | -15.5 M | -21.1 M | -18 M | -15.3 M | -18.9 M | -14.5 M | -13.1 M | -18.3 M | -8.4 M |
Operating Expenses |
- | - | - | - | 88.7 M | 95.4 M | 94.4 M | 96.1 M | 108 M | 111 M | 123 M | 125 M | 131 M | 144 M | 126 M | 118 M | 127 M | 112 M | 103 M | 87.2 M | 80.2 M | 77.3 M | 72.4 M | 63.2 M | 67.2 M | 64 M | 157 M | 85 M | 147 M | 97.3 M | 68.3 M | 64.2 M | 53.9 M | 41.1 M | 35 M | 42.1 M | 28.5 M | 20.4 M | 19.3 M | 15.6 M | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | 30.4 M | 32.6 M | 29.2 M | 33.3 M | 32.2 M | 32.9 M | 29.9 M | 40.8 M | 38.6 M | 41.9 M | 42.6 M | 45.2 M | 41.8 M | 48 M | 47.8 M | 49.1 M | 42.5 M | 44.9 M | 39.3 M | 38.5 M | 35 M | 36.1 M | 29.2 M | 12.2 M | 9.16 M | 9.55 M | 9.83 M | 8.24 M | 8.33 M | 7.2 M | 6.75 M | 5.6 M | 5.27 M | 5.26 M | 5.32 M | 5.54 M | 4.31 M | 3.49 M | 3.22 M | 2.77 M | 2.76 M | 2.68 M | 2.42 M | 2.04 M | 1.71 M | 1.7 M | 1.4 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Clovis Oncology (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
